drugset / Trial / NCT05765500
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
Phase 2
Recruiting
110 enrolled
Dana-Farber Cancer Institute
Myovant Sciences GmbH · collabPfizer · collabProstate Cancer Foundation · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. The drugs are already standard treatment for people with prostate cancer, and the drugs will be used as described in their label. The names of the study drugs involved in this study are: * Leuprolide (type of ADT) * Relugolix (type of ADT)
Timeline
- Start
- 2024-02-12
- Primary completion
- 2027-07-01
- Completion
- 2028-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Leuprolide | Other / unclassified | — | Intramuscular |
| Subject | Relugolix | Small molecule | — | Oral |